lysophosphatidic acid has been researched along with 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonylamino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid methyl ester in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Im, DS; Ishii, S; Kimura, T; Komachi, M; Mogi, C; Ohta, H; Okajima, F; Sato, K; Takeyoshi, I; Tobo, M; Tomura, H; Yamada, T; Yanagida, K | 1 |
| Lin, W; Liu, BL; Pan, HL; Zhang, YQ | 1 |
2 other study(ies) available for lysophosphatidic acid and 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonylamino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid methyl ester
| Article | Year |
|---|---|
Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
Topics: Animals; Ascites; Cell Line, Tumor; Cell Movement; Humans; Isoxazoles; Lysophospholipids; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Propionates; Receptors, Lysophosphatidic Acid; Xenograft Model Antitumor Assays | 2012 |
Modulation of Nav1.8 by Lysophosphatidic Acid in the Induction of Bone Cancer Pain.
Topics: Animals; Biophysics; Bone Neoplasms; Cancer Pain; Carcinoma; Disease Models, Animal; Electric Stimulation; Enzyme Inhibitors; Female; Ganglia, Spinal; Gene Expression Regulation, Neoplastic; Hyperalgesia; Isoxazoles; Lysophospholipids; Membrane Potentials; NAV1.8 Voltage-Gated Sodium Channel; Neurons; Pain Measurement; Patch-Clamp Techniques; Propionates; Rats; Rats, Sprague-Dawley; Receptors, Lysophosphatidic Acid | 2016 |